Immune System Biotech Odyssey Seeks $238.3 Million in US IPO
Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to raise $238.3 million in an initial public offering.
By Avalon Pernell · Bloomberg
Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to raise $238.3 million in an initial public offering.